STOCK TITAN

JAMA Study Using Alamar Biosciences’ NULISA Assay Links Blood eMTBR-tau to Tau tangle Burden in Former Football Players with Advanced CTE

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Alamar Biosciences (ALMR) announced a JAMA study that used its NULISA blood test and linked higher eMTBR-tau levels to more tau tangles in the brain.

The study included 21 former American football players who gave blood during life and later donated their brains. Eighteen had chronic traumatic encephalopathy (CTE), including 16 with high-stage disease. Blood levels of eMTBR-tau, a protein fragment, were higher in players with high-stage CTE than in those with low-stage or no CTE.

The test is not diagnostic or available for clinical use. CTE can still be confirmed only by examining the brain after death, and the researchers said the findings need validation in larger, more diverse groups.

Loading...
Loading translation...

Positive

  • Minor pointAlamar’s NULISA assay measured higher blood eMTBR-tau in high-stage CTE than in low-stage or no CTE
  • Minor pointBlood eMTBR-tau levels rose with the amount of tau tangles in the brain
  • Minor point. Forward-looking: it has not happened yet and may not happen.The two blood markers may help researchers distinguish CTE from Alzheimer’s disease
  • Minor pointA separate JAMA study used a NULISA-based assay to assess tau pathology in plasma from 728 research participants

Negative

  • Minor pointAlamar’s assay is not a diagnostic tool and is not available for clinical use
  • Minor pointThe early study included 21 former football players and needs validation in larger, more diverse groups

News Explained

Researchers found p-tau217 elevated only in people with Alzheimer’s pathology and not associated with CTE; together with eMTBR-tau, it may help researchers distinguish the conditions.

Key Figures

Study participants: 21 former American football players Participants with CTE: 18 participants High-stage CTE cases: 16 participants +1 more
Study participants
21 former American football players
Blood samples were collected during life; participants later donated their brains for research
Participants with CTE
18 participants
Of the 21 former players in the study
High-stage CTE cases
16 participants
Among the 18 participants with CTE
CTE cases with Alzheimer’s disease
5 cases
eMTBR-tau levels were highest in people with both conditions

Key Terms

cte, single-plex assay, p-tau217
3 terms
cte medical
"identify chronic traumatic encephalopathy (CTE) pathology in living patients"
Chronic Traumatic Encephalopathy (CTE) is a progressive brain condition linked to repeated head impacts that can cause memory loss, mood changes and impaired thinking; it is most often confirmed after death. Think of it as long-term wear-and-tear on the brain’s wiring. Investors watch CTE because research, lawsuits, regulatory action or changing safety standards can create legal costs, liability, insurance exposure and reputational damage that affect a company’s finances and future sales.
single-plex assay technical
"NULISAqpcr™ eMTBR-tau single-plex assay"
A laboratory test designed to detect or measure only one specific analyte, target molecule, or biomarker in a single reaction or sample. It runs a single assay per well or tube, using reagents and detection methods optimized for that one target; unlike multiplex assays, it cannot simultaneously measure multiple targets in the same reaction. Practical consequences include simpler assay design and interpretation but requiring separate runs or samples for each additional target.
p-tau217 medical
"The researchers also measured p-tau217, an established blood marker for Alzheimer’s disease"
p-tau217 is a specific form of the tau protein that has a phosphate tag at position 217 and is measured in blood or spinal fluid as a biomarker for Alzheimer’s disease. It matters to investors because changes in p-tau217 can signal whether a drug is affecting the underlying disease or whether a diagnostic test can detect Alzheimer’s earlier, which can drive regulatory approvals, market demand for tests, and the commercial success of therapies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Findings point to a possible blood-based approach for studying CTE in living people

FREMONT, Calif., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced new research published in the Journal of the American Medical Association (JAMA). Researchers at Boston University CTE Center, with collaborators at Banner Health and more than 20 Institutions, used Alamar’s NULISAqpcr™ eMTBR-tau single-plex assay to evaluate whether a blood test could identify chronic traumatic encephalopathy (CTE) pathology in living patients.

The researchers found higher blood levels of eMTBR-tau in former football players with advanced CTE and that levels rose with the amount of tau tangle pathology in the brain. eMTBR-tau is a protein fragment linked to the tau tangles seen in CTE and Alzheimer’s disease. CTE is a. neurodegenerative disease associated with repeated head impacts. Today it can only be confirmed by examining the brain after death. The finding could give researchers a way to study CTE during life.

“CTE has been extraordinarily difficult to study because doctors cannot confirm it in a living person. Proteins like eMTBR-tau have recently been associated with neuropathology but are present at very low levels in blood,” said Yuling Luo, PhD, founder, CEO and chair of Alamar Biosciences. “Our NULISA technology was built to measure low abundant proteins, and a reliable, simple blood test for CTE would enable new research into the progression and treatment of this debilitating illness. There is more work to do, but studies like this one show why that effort matters.”

The study included 21 former American football players who gave blood samples during life and later donated their brains for research through Boston University CTE Center Studies. Eighteen had CTE, including 16 with high-stage disease. Plasma eMTBR-tau was significantly higher in high-stage CTE than in low-stage CTE or no CTE. Five of the CTE cases also had Alzheimer’s disease, and eMTBR-tau levels were highest in people who had both conditions. The researchers also measured p-tau217, an established blood marker for Alzheimer’s disease. It was elevated only in people with Alzheimer’s pathology and was not associated with CTE. Used together, the two markers may help researchers tell the conditions apart.

The study suggests a promising new biomarker approach to accurately detecting CTE pathology through a blood test, with the potential to improve patient diagnosis, identification and enrollment in clinical trials, and support the development of targeted therapies. The researchers describe the results as an early study that requires validation in larger and diverse cohorts. The test is not a diagnostic tool and is not available for clinical use. To date, no blood test has yet been validated for diagnosing CTE in living patients.

“Having blood tests that accurately determine the underlying pathology, which are now approved for use in Alzheimer’s disease, has been revolutionary in the way we diagnose patients and design therapeutic trials,” said Nicholas Ashton, PhD, co-senior author of the study and senior director of Banner Health’s Fluid Biomarker Program. “With this new study, we are optimistic this biomarker will spur a serious discussion about treatment development for CTE.”

Dr. Ashton’s work also includes blood-based eMTBR-tau measurement in Alzheimer’s disease, most recently in a JAMA study published November 16 that used a NULISA-based assay to assess tau pathology in plasma from 728 research participants.

About Alamar Biosciences

Alamar is a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Leveraging our proprietary NULISA™ technology and the ARGO® HT System, our platform is designed to detect protein biomarkers at extremely low concentrations in blood with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, helping researchers unlock the full spectrum of protein biomarkers across disease states. Learn more at alamarbio.com.

Forward Looking Statements

This press release may contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding Alamar’s NULISA platform’s capabilities, performance and impact on CTE research on live patients. Any forward-looking statements in this press release are based on Alamar Biosciences’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Readers are cautioned that actual results could differ materially from those expressed or implied in Alamar Biosciences’ forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to intense competition in the proteomics market, exposure to legal proceedings, regulatory inquiries and other legal matters, failure to develop new assays or instruments, dependence on researchers who rely heavily on government funding, reductions in spending by research and academic institutions, the potential for products to be subject to more onerous regulation by the FDA or other regulatory requirements, the complexity of manufacturing Alamar Biosciences’ instruments and consumables, failure to obtain marketing authorizations for future products that are intended for clinical or diagnostic use, Alamar Biosciences’ ability to protect its intellectual property, and the other risks described in Alamar Biosciences’ filings with the U.S. Securities and Exchange Commission, including its Quarterly Report on Form 10-Q filed with the SEC on August 11, 2026. Alamar Biosciences explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Media Contact:
Media@alamarbio.com

Investor Contact:
Investors@alamarbio.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the JAMA CTE study using Alamar Biosciences’ NULISA assay find?

The study found higher blood eMTBR-tau levels in high-stage CTE than in low-stage CTE or no CTE. Levels also rose with the amount of tau tangles found in the brain.

How did the Alamar NULISA CTE study compare blood markers for CTE and Alzheimer’s disease?

The study found that p-tau217, an established Alzheimer’s blood marker, was elevated only in people with Alzheimer’s pathology and was not associated with CTE. Five people with CTE also had Alzheimer’s disease, and eMTBR-tau levels were highest in people with both conditions.

Keep reading